# Rocket Pharmaceuticals, Inc. (RCKT) insider trading

> In the 12 months to Nov 14, 2026, 6 RCKT insiders reported open-market sales of $1.0M across 27 filings; one director bought $34.4K.

Canonical: https://massive.com/quote/rckt/insider-trading
Latest filing: 2026-11-12 (last 12 months; source: SEC EDGAR)
Source: Massive (https://massive.com/docs/llms.txt)

## Summary

| Measure | Value | Detail |
| --- | --- | --- |
| Open-market sales | $1.0M | 27 filings · 6 insiders |
| Open-market purchases | $34.4K | 1 filing · Elisabeth Bjork, Director |

## Open-market trades by insider

| Insider | Role | Sold | Bought | Filings | Pre-arranged (10b5-1) | Last filed |
| --- | --- | --- | --- | --- | --- | --- |
| Martin Wilson | General Counsel | $462.4K | — | 9 | — | 2026-11-09 |
| Gaurav Shah | CEO | $285.7K | — | 8 | — | 2026-08-20 |
| Christopher James Stevens | Chief Operating Officer | $128.3K | — | 1 | — | 2026-08-13 |
| Sarbani Chaudhuri | Officer (see filing) | $95.5K | — | 3 | — | 2026-11-12 |
| Elisabeth Bjork | Director | — | $34.4K | 1 | — | 2026-01-06 |
| John Militello | Officer (see filing) | $23.7K | — | 5 | — | 2026-05-21 |
| Jonathan David Schwartz | Officer (see filing) | $7.6K | — | 1 | — | 2025-11-20 |

## Open-market trades by filing

28 filings in the last 12 months, newest first.

| Filed | Traded | Insider | Role | Type | Shares | Avg price | Value | Held after | Filing |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| 2026-11-12 | 2026-11-09 | Sarbani Chaudhuri | Officer (see filing) | Sale | 4,872 | $2.33 | $11.3K | 257,937 | — |
| 2026-11-09 | 2026-11-05 | Martin Wilson | General Counsel | Sale | 53,389 | $2.39 | $127.8K | 545,100 | — |
| 2026-09-15 | 2026-09-11 | Martin Wilson | General Counsel | Sale | 75,364 | $3.40 | $256.5K | 598,489 | — |
| 2026-08-20 | 2026-08-18 | Gaurav Shah | CEO | Sale | 2,293 | $3.38 | $7.8K | 1,056,594 | — |
| 2026-08-20 | 2026-08-18 | Martin Wilson | General Counsel | Sale | 631 | $3.38 | $2.1K | 673,853 | — |
| 2026-08-17 | 2026-08-13 | Martin Wilson | General Counsel | Sale | 3,493 | $3.38 | $11.8K | 674,484 | — |
| 2026-08-17 | 2026-08-13 | Gaurav Shah | CEO | Sale | 2,837 | $3.38 | $9.6K | 1,058,887 | — |
| 2026-08-13 | 2026-08-11 | Sarbani Chaudhuri | Officer (see filing) | Sale | 4,701 | $3.50 | $16.4K | 262,809 | — |
| 2026-08-13 | 2026-08-11 | Christopher James Stevens | Chief Operating Officer | Sale | 36,658 | $3.50 | $128.3K | 505,784 | — |
| 2026-05-26 | 2026-05-21 | Gaurav Shah | CEO | Sale | 55,684 | $3.09 | $171.8K | 1,061,724 | — |
| 2026-05-21 | 2026-05-19 | John Militello | Officer (see filing) | Sale | 384 | $3.01 | $1.2K | 89,780 | — |
| 2026-05-21 | 2026-05-19 | Martin Wilson | General Counsel | Sale | 662 | $3.01 | $2.0K | 677,977 | — |
| 2026-05-21 | 2026-05-19 | Gaurav Shah | CEO | Sale | 2,409 | $3.01 | $7.3K | 1,040,918 | — |
| 2026-05-14 | 2026-05-13 | John Militello | Officer (see filing) | Sale | 855 | $3.61 | $3.1K | 90,164 | — |
| 2026-05-14 | 2026-05-13 | Gaurav Shah | CEO | Sale | 2,728 | $3.61 | $9.8K | 1,043,327 | — |
| 2026-05-14 | 2026-05-13 | Martin Wilson | General Counsel | Sale | 3,361 | $3.61 | $12.1K | 678,639 | — |
| 2026-05-11 | 2026-05-07 | Sarbani Chaudhuri | Officer (see filing) | Sale | 17,650 | $3.84 | $67.7K | 267,510 | — |
| 2026-02-20 | 2026-02-18 | Martin Wilson | General Counsel | Sale | 1,376 | $3.34 | $4.6K | 682,000 | — |
| 2026-02-20 | 2026-02-18 | Gaurav Shah | CEO | Sale | 5,990 | $3.34 | $20.0K | 1,046,055 | — |
| 2026-02-20 | 2026-02-18 | John Militello | Officer (see filing) | Sale | 1,157 | $3.34 | $3.9K | 91,019 | — |
| 2026-02-18 | 2026-02-13 | Gaurav Shah | CEO | Sale | 12,279 | $3.31 | $40.7K | 1,052,045 | — |
| 2026-02-18 | 2026-02-13 | John Militello | Officer (see filing) | Sale | 3,726 | $3.31 | $12.3K | 92,176 | — |
| 2026-02-18 | 2026-02-13 | Martin Wilson | General Counsel | Sale | 12,253 | $3.31 | $40.6K | 683,376 | — |
| 2026-01-06 | 2026-01-02 | Elisabeth Bjork | Director | Purchase | 10,000 | $3.44 | $34.4K | 50,000 | — |
| 2025-11-20 | 2025-11-18 | Martin Wilson | General Counsel | Sale | 1,646 | $2.98 | $4.9K | 383,816 | — |
| 2025-11-20 | 2025-11-18 | Gaurav Shah | CEO | Sale | 6,276 | $2.98 | $18.7K | 778,296 | — |
| 2025-11-20 | 2025-11-18 | Jonathan David Schwartz | Officer (see filing) | Sale | 2,545 | $2.98 | $7.6K | 299,064 | — |
| 2025-11-20 | 2025-11-18 | John Militello | Officer (see filing) | Sale | 1,086 | $2.98 | $3.2K | 65,920 | — |

## Other insider activity (not market trades)

- Option exercises: 1 record
- Grants and awards: 13 records
- Other: 1 record

Reported on Form 4 but not purchases or sales in the market, so not counted in the totals above.

## How to read this page

- **Open-market purchase or sale**: A buy or sell of the company's stock at market price. Grants, option exercises, shares withheld for tax, gifts and employee stock plan purchases are listed separately and not counted.
- **Filing date**: Insiders have two business days to report a trade. Totals and the chart use the filing date, when the trade became public.

## FAQ

### Has Rocket Pharmaceuticals, Inc.'s CEO sold stock?

Yes. Gaurav Shah (CEO) sold 90,496 shares ($285.7K) between Nov 2025 and Aug 2026.

### How current is RCKT’s insider data?

These are RCKT Form 4 filings from the last year, refreshed daily. The Massive Form 4 API has the full, continuously updated record.

### What counts as an open-market buy or sell?

Only purchases and sales at the market price. Option exercises, grants, gifts, and shares withheld for taxes are reported on Form 4 but are left out of the buy and sell totals.

## Live data

This page joins two Massive endpoints: Form 4 filings and daily prices. The RCKT Form 4 request:

- `GET https://api.massive.com/stocks/filings/vX/form-4?tickers=RCKT&filing_date.gte=2025-11-14&sort=filing_date.desc&limit=500`

Requests need a Massive API key. API reference for agents: https://massive.com/docs/llms.txt. Connect an AI agent through the Massive MCP server: https://massive.com/docs/ai-tools.

## Related

- [Rocket Pharmaceuticals, Inc. (RCKT) stock price](https://massive.com/quote/rckt.md)
- [Recent insider trading](https://massive.com/quote/insider-trading.md)
- [Markets overview](https://massive.com/quote/index.md)

Nothing here is investment advice. Data and content are provided for informational purposes under the Massive Terms of Service: https://massive.com/terms
